Associated Papers
Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.
Cross WCH et al.
Cancer Discovery, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
Klocker EV et al.
Npj Breast Cancer, 2025
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs.
Wang P et al.
Genome Biology, 2025
Effects of PIK3CA Gene Modifications on Radiosensitivity in Colorectal Cancer Cells.
Alsbeih G et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2025
Comprehensive Genomic Profiling of Indian Patients With Lung Cancer.
Sharma S et al.
Jco Global Oncology, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer.
Sun Z et al.
Journal for Immunotherapy of Cancer, 2025
Delineation of the phenotypes and genotypes of PIK3CA-related overgrowth spectrum in East asians.
Chen H et al.
Molecular Genetics and Genomics : Mgg, 2024
Characterizing multi-PIK3CA mutations across cancer types: Toward precision oncology.
Nakamura K et al.
Cancer Medicine, 2024
Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.
Mussa A et al.
Journal of Medical Genetics, 2023
Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.
Voutsadakis IA
Medicina (kaunas, Lithuania), 2022
Clinical and genetic analyses of patients with lateralized overgrowth.
Kim YM et al.
Bmc Medical Genomics, 2022
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
Chong X et al.
Molecular Cancer, 2022
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.
Omura T et al.
Cancers, 2022
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.
Voutsadakis IA
Medical Oncology (northwood, London, England), 2022
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.
Xu J et al.
Cancer Discovery, 2021
Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literature.
Maines E et al.
Hormones (athens, Greece), 2021
Challenges in bioinformatics approaches to tumor mutation burden analysis.
Fenizia F et al.
Oncology Letters, 2021
Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN.
Codrich M et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2021
Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways.
Cho JH et al.
Cell Death and Differentiation, 2021
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
Charo LM et al.
Molecular Oncology, 2021
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D et al.
International Journal of Molecular Sciences, 2020
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH et al.
Journal for Immunotherapy of Cancer, 2020
The mutational landscape of normal human endometrial epithelium.
Moore L et al.
Nature, 2020
[Impact of prenylation inhibition on RAS mutant tumors in preclinical studies].
Baranyi M et al.
Magyar Onkologia, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL et al.
Nature Communications, 2019
Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL et al.
International Journal of Cancer, 2019
Whole-exome sequencing insights into pulmonary artery sarcoma mimicking pulmonary embolism: a case report and review.
Wu Y et al.
Oncotargets and Therapy, 2019
Contribution of allelic imbalance to colorectal cancer.
Palin K et al.
Nature Communications, 2018
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
Manic G et al.
Gut, 2018
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L et al.
Nature Communications, 2018
Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer.
Suhaimi SS et al.
Frontiers in Pharmacology, 2018
Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing.
Kuentz P et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2016
The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth.
Nivarthi H et al.
Oncotarget, 2016
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Hao Y et al.
Nature Communications, 2016
PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.
Mirzaa G et al.
Jci Insight, 2016